PP
DMTX

Paloma Partners’s Dimension Therapeutics, Inc DMTX Stock Holding History

Paloma Partners’s Portfolio DMTX Stock Details DMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-31,800
Closed -$46K – 2730
2017
Q2 		$46K Buy
+31,800
New +$43.2K ﹤0.01% 2110

Other funds holding DMTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Paloma Partners's DMTX Position: Q3 2017 in Review

Paloma Partners sold out of Dimension Therapeutics, Inc (DMTX) in Q3 2017, closing a stake of 31,800 shares — an estimated $46K sold.

Paloma Partners first reported a position in DMTX in Q2 2017 and held it in 1 quarter. The position peaked at $46K in Q2 2017. 34 funds tracked by Wall St. Rank hold DMTX as of Q3 2017.

  • Paloma Partners reported no remaining Dimension Therapeutics, Inc position as of Q3 2017 after selling out during the quarter.
  • Paloma Partners sold 31,800 Dimension Therapeutics, Inc shares in Q3 2017, an estimated $46K.
  • Paloma Partners first reported a position in Dimension Therapeutics, Inc in Q2 2017 and held it in 1 quarter.
  • Paloma Partners's Dimension Therapeutics, Inc position peaked at $46K in Q2 2017.
  • 34 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.